BioSpace News Archive

CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced data on the compassionate use of beremagene geperpavec (B-VEC), administered as an eyedrop to treat a patient with dystrophic epidermolysis bullosa (DEB) with cicatrizing conjunctivitis has been published in the New England Journal of Medicine (NEJM).

Amicus Therapeutics (Nasdaq: FOLD), today announced that WORLD Symposium™ has awarded Pombiliti™ ( cipaglucosidase alfa-atga ) + Opfolda™ ( miglustat ) the 2024 New Treatment Award, which recognizes important achievements in advancing treatments for lysosomal diseases which have attained regulatory approval.

CytoSorbents Corporation announces that Dr. Phillip Chan, Chief Executive Officer, will present at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA on Wednesday, March 6th, 2024.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with wet age-related macular degeneration (AMD).

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has entered into a multi-year agreement with the Vector Institute in Toronto, an independent not-for-profit corporation dedicated to advancing the field of artificial intelligence (AI) through world-class research.

Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results.

Domain Therapeutics today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.

Theralase Technologies Inc. is pleased to announce that Dr. Michael Jewett has joined Theralase in the role of an independent consultant, to assist the Company in the completion of enrollment of patients in the Phase II Bacillus Calmette-Guérin (“BCG”)-Unresponsive Non Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) clinical study (“Study II”).

AmplifyBio CEO J. Kelly Ganjei Discusses Solutions for Reducing Costs and Risk in Advanced Therapy Manufacturing During Fireside Chat at Advanced Therapies Week.